<DOC>
	<DOCNO>NCT01720888</DOCNO>
	<brief_summary>Despite recent advance medical surgical treatment , heart failure result ischemic cardiomyopathy ( ICM ) remain leading cause cardiovascular mortality . Ischemic dilate cardiomyopathy ( ICM ) define abnormally enlarge leave ventricular ( LV ) cavity document poor LV function result severe coronary artery disease ( CAD ) . LV remodelling inevitable infarct postulate contribute largely poor outcome patient ICM , therefore prevention LV remodelling goal treatment patient severe CAD . Cell therapy represent novel therapeutic strategy treat cardiac disease include severe CAD heart failure . A type stem cell know mesenchymal stem cell ( MSCs ) isolate bone marrow.This study aim test differentiation potential therapeutic capacity MSC severe CAD patient intracoronary implantation ischemic myocardial environment Malaysian population .</brief_summary>
	<brief_title>Intracoronary Autologous Mesenchymal Stem Cells Implantation Patients With Ischemic Dilated Cardiomyopathy</brief_title>
	<detailed_description>Ischemic dilate cardiomyopathy ( ICM ) define abnormally enlarge leave ventricular ( LV ) cavity document poor LV function result severe coronary artery disease ( CAD ) . LV remodelling inevitable infarct postulate contribute largely poor outcome patient ICM , therefore prevention LV remodelling goal treatment patient severe CAD . Cell therapy represent novel therapeutic strategy treat cardiac disease include severe CAD heart failure . A type stem cell know mesenchymal stem cell ( MSCs ) isolate bone marrow . Experimental clinical study date show mesenchymal stem cell represent suitable cell type regeneration therapy myocardial infarction ( MI ) . After injection ischemic myocardium , bone marrow-derived MSC ( BM-MSC ) various animal specie differentiate multiple cell lineage , include endothelial cell cardiomyocytes , thereby improve LV function . In Malaysia previously demonstrate capability isolate extract MSC small volume bone marrow aspirates.The isolation , expansion feasibility storage , transport differentiation human MSC clinical application perform locally . The researcher use autologous BM-MSC , ex vivo expand , three patient end-stage ischemic dilate cardiomyopathy heart transplant wait list patient inject MSCs directly myocardium open heart surgery . After twelve month , patient remain alive well significant improvement cardiac function , quality life parameter include reduction myocardial scar volume see cardiac scan . The group researcher carry study ten patient severe dilate cardiomyopathy refractory cardiac function despite maximum medical therapy receive autologous BM-MSC implantation via intramyocardial intracoronary route . All patient remain alive 1 year record significant improvement LV ejection fraction LV parameter baseline 6 12 month . Reduction scar also note six patient 12 month . Following result , study aim test differentiation potential therapeutic capacity MSC severe CAD patient intracoronary implantation ischemic myocardial environment Malaysian population .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<criteria>age 35 75 year diagnose ICM confirm previous coronary angiogram show significant coronary artery disease &gt; 70 % history previous myocardial infarction . myocardial infarction event occur 6 month long time screen . LV ejection fraction â‰¤40 % echocardiogram cardiac MRI . Likelihood heart failure cause idiopathic , infective metabolic cardiomyopathy , valvular heart disease pericardial disease . patient undergone coronary artery bypass graft ( CABG ) procedure . patient visible/significant myocardial scar . patient cardiovascular metallic implantation . contraindication bone marrow aspiration contraindication coronary contrast angiography angioplasty . acute chronic communicable disease include Hepatitis B , Hepatitis C HIV . past history neoplasia primary haematological disease . current , past paroxysmal cardiac arrhythmia . renal impairment indicate creatinine clearance le 30 ml/min . liver impairment indicated serum alanine transferase level 4 time great normal value .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Autologous</keyword>
	<keyword>Bone Marrow</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>Ischemic Dilated Cardiomyopathy</keyword>
</DOC>